908 Devices Q2 2026 earnings: Revenue rises 23% as EBITDA loss narrows

908 Devices (NASDAQ: MASS) reported Q2 2026 revenue of $16.1 million, up 23% from $13.0 million a year earlier, while its GAAP diluted loss per share from continuing operations narrowed to $0.32 from $0.36. Product revenue from VipIR and the addition of NIRLab revenue supported growth, while the adjusted EBITDA loss fell by more than half to $1.9 million.

Core financial results

Revenue growth outpaced operating expense growth, allowing both GAAP gross margin and adjusted gross margin to improve. Total operating expenses declined slightly, but remained well above quarterly gross profit, leaving the company unprofitable on both a GAAP and adjusted basis.

The adjusted EBITDA improvement was more pronounced than the change in GAAP net loss because the non-GAAP measure excludes contingent consideration adjustments, stock-based compensation, amortization, and acquisition-related costs.

Business and product performance

Product revenue increased about 35% to $13.0 million from $9.6 million, driven by higher VipIR revenue and the addition of NIRLab. In contrast, service and contract revenue declined about 10% to $3.1 million from $3.5 million. The shift toward product sales, together with a change in channel mix, was the main disclosed reason for the higher adjusted gross margin.

The installed base reached 4,101 devices, up 23% year over year, after 198 devices were placed during the quarter. More than 35 VipIR chemical identification devices were shipped, including 18 units delivered to a major South Asian law enforcement agency. Cumulative VipIR shipments have now exceeded 100 units since launch.

Recurring revenue was $4.9 million, representing 31% of total quarterly revenue. Management also said U.S. state and local customers generated more than half of revenue, reflecting continued demand from agencies modernizing their chemical detection capabilities.

Profitability, cash, and the balance sheet

The modest decline in total operating expenses masked changes within the expense base. Research and development expense fell to $3.6 million from $4.4 million, while selling, general and administrative expense increased to $11.1 million from $10.3 million. Operating expenses also included a $6.4 million change in the fair value of contingent consideration, compared with $6.8 million a year earlier.

Cash, cash equivalents, and marketable securities totaled $101.5 million at June 30, 2026, down from $113.0 million at the end of 2025. The company had no outstanding debt. During Q2, it used $13.5 million of cash for the NIRLAB SA acquisition and received $3.5 million from the release of escrow related to its desktop business divestiture.

Inventory increased to $14.4 million from $13.0 million at year-end. The balance sheet also reflected the acquisition, including $11.1 million of goodwill and an increase in net intangible assets to $45.1 million from $36.4 million.

Adjusted profitability is improving faster than the GAAP loss

The adjusted EBITDA loss narrowed by approximately $2.0 million, but the GAAP net loss from continuing operations improved by only about $1.0 million. The difference largely reflects items excluded from adjusted EBITDA, including $6.4 million of contingent consideration expense, $2.3 million of stock-based compensation, $0.9 million of intangible amortization, and $0.7 million of acquisition and integration costs.

This distinction matters because the underlying operating trend improved as revenue and gross profit expanded, but acquisition-related and noncash accounting charges continued to weigh heavily on reported results. The company therefore remains some distance from GAAP profitability despite the progress in adjusted EBITDA.

2026 guidance

908 Devices raised the low end of its full-year revenue outlook by $1 million while leaving the high end unchanged. The revised range represents expected growth of 21% to 25% over 2025 revenue.

After the quarter ended, the company secured a $6 million ProtectIR order from a corrections agency in the Asia-Pacific region. Management cited the order as additional support for its second-half revenue outlook, although the release did not specify the exact timing of revenue recognition.

Recent insider transactions

The supplied insider transaction data shows several reported sales by directors, the CEO, and a beneficial owner around and after the end of the quarter. These transactions are presented without drawing conclusions about insiders’ views of the company’s prospects.

Risks investors should watch

• Continuing losses: The adjusted EBITDA loss improved substantially, but 908 Devices still reported a $11.9 million GAAP loss from continuing operations. Operating expenses remained more than twice the level of gross profit.
• Second-half execution: Achieving the raised $68 million to $70 million revenue outlook depends on converting the opportunity pipeline and agency orders into recognized revenue during the remainder of 2026.
• Acquisition and accounting costs: NIRLAB added revenue and expanded the product offering, but the acquisition required $13.5 million of cash and contributed to integration costs and a larger intangible asset balance. Contingent consideration adjustments also create volatility in GAAP results.
• Customer and order concentration: U.S. state and local agencies represented more than half of quarterly revenue, while individual international agency orders can be sizable. The timing of such orders may affect quarterly revenue patterns.
• Service revenue decline: Service and contract revenue fell year over year even as product revenue increased. A continued decline could limit diversification in the company’s revenue mix.

Summary

908 Devices’ Q2 2026 results showed improving operating momentum: product-led revenue growth lifted margins, and the adjusted EBITDA loss was cut by more than half. However, GAAP losses remained substantial because operating costs and acquisition-related accounting charges continued to outweigh gross profit. Execution on the raised revenue outlook, integration of NIRLab, and the conversion of large government opportunities into revenue are the main items to monitor during the second half of 2026.